Clinical trials: Induction Chemotherapy
Nausea and Vomiting, Chemotherapy-Induced
Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting
This is a multicenter, randomized, double-blind, active-controlled dose-finding study. About 180 subjects who receive a high emetic chemotherapy are planned to be enrolled and randomized into three groups by a ratio of 1:1:1.
- Trial name
- CINV (NCT06593782)
- Testing
- HSK21542, Dolasetron
- Volunteers
- 180 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Breast Cancer
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
The primary objective is to evaluate the difference in cardiac strain rate evolution in elderly early BC patients treated with (neo) adjuvant anthracycline-based chemotherapy compared with a non-anthracycline regimen…
- Trial name
- NCT01301040
- Testing
- epirubicin, cyclophosphamide, docetaxel
- Where
- Belgium
- Volunteers
- 2 people
- Sponsor
- Jules Bordet Institute
Neoplasms, Chemotherapy-induced Neutropenia
Study to Evaluate the Usability of PointCheck
This a study about the usability of PointCheck a novel non-invasive technology for monitoring chemotherapy-induced neutropenia. The study will include patients with cancer visiting the outpatient hematology clinic for their…
- Trial name
- NCT04448314
- Testing
- PointCheck
- Where
- 3 sites in Spain
- Volunteers
- 94 people
- Sponsor
- Leuko Labs, Inc.
Chemotherapy-induced Peripheral Neuropathy
Spinal Cord Stimulation in Chemotherapy Induced Neuropathy
This is an observational based pilot study evaluating the use of spinal cord stimulators for the treatment of chemotherapy induced peripheral neuropathy will lead to an increase in quality of life and decrease in pain.
- Trial name
- NCT03764514
- Testing
- Spinal Cord Stimulator
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Prisma Health-Upstate
Pancreatic Cancer
A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
This is a dose escalation trial to evaluate the safety of stereotactic body radiotherapy (SBRT) delivered in 3 fractions for patients with locally advanced pancreatic cancer (LAPC) who have received induction chemotherapy…
- Trial name
- NCT02873598
- Testing
- FOLFIRINOX or gemcitabine/abraxane, SBRT
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Colorado, Denver
Chemotherapy-induced Nausea and Vomiting
Effectiveness of Laserpuncture and Standard Antiemetic on RINVR Scores in Adolescent Patients Undergoing Chemotherapy
Chemotherapy is a common treatment for treating cancer. Chemotherapy induced nausea and vomiting (CINV) is nausea and vomiting that occurs after chemotherapy.
- Trial name
- NCT06121414
- Testing
- laserpuncture
- Where
- 2 sites in Indonesia
- Volunteers
- 58 people
- Sponsor
- Universitas Indonesia
Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination with nivolumab followed by FOLFIRI reintroduction, versus FOLFIRI as maintenance…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer
- Trial name
- TEDOPAM (NCT03806309)
- Testing
- FOLFIRI, OSE2101
- Where
- 28 sites in France
- Volunteers
- 106 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Breast Neoplasms, Metastases, Neoplasm
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
This study will evaluate the effectiveness of chemotherapy and a combination of vaccines to treat metastatic breast cancer (breast cancer that has spread beyond the breast) in patients whose cancer cells have a protein called…
- Trial name
- NCT00048893
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)/TRICOM vaccine, filgrastim
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): Oro-, Hypopharyngeal and Laryngeal Cancer
TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors
TPF-C-HIT investigates the combination of induction chemotherapy with TPF followed by radioimmunotherapy with cetuximab and IMRT plus carbon ion boost with regard to efficacy and toxicity of the combination regimen.
- Trial name
- TPF-C-HIT (NCT01245985)
- Testing
- carbon ion boost
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Heidelberg University
Lung Cancer
Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as vinorelbine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00253591
- Testing
- cisplatin, vinorelbine tartrate, radiation therapy
- Where
- 20 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Medical Research Council
Cancer, Malignancy
Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone
The purpose of this study is to assess the efficacy and safety of Ramosetron, Aprepitant and Dexamethasone therapy versus Ondansetron, Aprepitant and Dexamethasone therapy for preventing of nausea and vomiting in highly…
- Trial name
- ROAD (NCT01536691)
- Testing
- ramosetron, ondansetron
- Where
- South Korea
- Volunteers
- 338 people
- Sponsor
- Hallym University Medical Center
Multiple Myeloma, Myeloma
Mobile Health Device Study for Myeloma Patients
Enrolled participants health status will be tracked by using a mobile health-monitoring device while undergoing chemotherapy for multiple myeloma.
- Trial name
- NCT03006315
- Testing
- Garmin Vivofit device, Mobile Health quality of life assessements
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Oral Mucositis
Low-energy Laser Therapy for Prevention of Oral Mucositis in Children
Oral mucositis represents a major complication of cytotoxic chemotherapy among cancer in children. Low-power laser therapy (LPLT) has been used to reduce the incidence of oral mucositis in patients who are receiving high-dose…
- Trial name
- NCT01007617
- Testing
- LLLT :low level laser therapy
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Clermont-Ferrand
Breast Cancer, Non Hodgkin Lymphoma
PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?
PROACT will establish the effectiveness of the angiotensin-converting enzyme inhibitor (ACEI) enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and non-Hodgkin lymphoma undergoing adjuvant…
- Trial name
- PROACT (NCT03265574)
- Testing
- Enalapril
- Where
- United Kingdom
- Volunteers
- 111 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Chemotherapy-induced Neutropenia
Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
Determination of the effect of neugranin on the duration and severity of severe neutropenia in participants receiving doxorubicin in combination with docetaxel.
- Trial name
- NEUGR-003 (NCT01126190)
- Testing
- Neugranin, Pegfilgrastim, Chemotherapy
- Where
- 59 sites in Bulgaria, Romania and 3 more
- Volunteers
- 381 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chemotherapy-induced Thrombocytopenia
A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11
This phases Ⅲ trials is divided into two stages,Ⅲa and Ⅲb.The aim of Ⅲa is to evaluate the optimal dosing dose of genetically modified recombinant human IL-11 (mIL-11) in a multicenter randomized self-control trial involving 60…
- Trial name
- NCT01663441
- Testing
- NL201, rhIL-11
- Where
- 5 sites in China
- Volunteers
- 62 people
- Sponsor
- Beijing Northland Biotech. Co., Ltd.
Nausea Post Chemotherapy, Vomiting
TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous electrical acupoint stimulation for cisplatin- chemotherapy induced nausea and vomiting.
- Conditions
- Nausea Post Chemotherapy, Vomiting, Transcutaneous Electrical Acupoint Stimulation, Acupuncture
- Trial name
- NCT07509905
- Testing
- Transcutaneous electrical nerve stimulation, Antiemetic
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- Cairo University
Non Small Cell Lung Cancer
Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
The purpose of this study is to evaluate the safety and efficacy of Camrelizumab in combination with platinum doublet neoadjuvant chemotherapy before surgery [neoadjuvant phase], followed by Camrelizumab alone after surgery…
- Trial name
- NEOSUN (NCT04943029)
- Testing
- Carrelizumab, Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chemo-radiation Induced Nausea and Vomiting
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
The purpose of this phase 2 study is to assess the efficacy and patient satisfaction of oral rolapitant plus ondansetron vs. oral ondansetron monotherapy in malignant glioma (MG) patients receiving standard of care radiation (RT)…
- Trial name
- NCT02991456
- Testing
- Rolapitant, Ondansetron
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Nausea, Vomiting
Treatment of Chemotherapy-induced Nausea and Vomiting
Delayed nausea is a common problem after high dose chemotherapy for bone marrow transplantation. This study wants to compare standard prophylactic anti-emetic therapy with the same treatment plus the drug aprepitant (Emend).
- Trial name
- NCT01101529
- Testing
- Aprepitant (Emend)
- Where
- Sweden
- Volunteers
- 90 people
- Sponsor
- Uppsala University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.